In Landmark Step, Acuity Is First Firm to Begin RNAi-based Drug Study In Humans | GenomeWeb

Acuity Pharmaceuticals said on Nov. 9 that the first patients in a phase I trial of the company’s investigational siRNA-based age-related macular degeneration treatment, Cand5, have been dosed, marking the first time that an RNAi drug is being used in humans.

“The trial is underway,” Sam Reich, Acuity’s senior director of researcher and development and co-founder, told RNAi News. “Multiple patients have been dosed, and everything’s been successful to date.

“The trial is in full swing and we’re very excited,” he added.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.